基于三基的线粒体向纳米载体:促进癌症治疗的进步
Mohd Shoab Ali1, B H Jaswanth Gowda2, Rahul Shukla3
1Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India.
Clinical pharmacology : advances and applications
|June 17, 2025
概括
纳米技术通过将药物直接输送到细胞的发电厂线粒体来增强癌症治疗. 纳米载体中的三 (TPP) 提高了药物向性,减少了副作用和剂量.
科学领域:
- 纳米医学是一种纳米医学.
- 癌症生物学 癌症生物学
- 线粒体医学 线粒体医学
背景情况:
- 化疗疗效率受到针对性和不良副作用的限制.
- 线粒体对细胞存活至关重要,并与癌症进展有关.
- 准线粒体提供了一种提高癌症治疗精度的策略.
研究的目的:
- 审查纳米技术在癌症治疗中的作用,重点关注线粒体向.
- 为了分析设计用于将药物输送到线粒体的纳米载体.
- 讨论在纳米载体系统中用于线粒体向的三基 (TPP) 的使用.
主要方法:
- 关于用于癌症治疗的纳米载体的科学文献的综述.
- 分析使用纳米输送系统的线粒体向策略.
- 对三基 (TPP) 作为线粒体向部分的检查.
主要成果:
- 纳米载体使化学疗法药物能够有针对性地向癌细胞和线粒体输送.
- 三基 (TPP) 显示出强大的线粒体向能力.
- 基于TPP的纳米载体可以降低药物剂量,并最大限度地降低目标外毒性.
结论:
- 纳米技术,特别是TPP修饰的纳米载体,对向癌症治疗具有显著的前景.
- 线粒体药物输送可以提高治疗结果并减少副作用.
- 需要进一步的研究来应对诸如TPP的溶血活性等挑战.
更多相关视频
09:02Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
2.8K
09:01Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy
Published on: May 22, 2020
3.2K
相关概念视频
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
01:46Electron Transport Chain: Complex I and II
15.1K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
15.1K